Gonorrhea

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Sites of Infection and Clinical Presentation
5. Complications
6. Diagnosis
7. Treatment
8. Antimicrobial Resistance
9. Prevention
10. Research Advances
11. Key Research Papers
12. PubMed Research Papers
13. Connections
14. Featured Videos

Overview

Gonorrhea is a common bacterial sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a gram-negative diplococcus bacterium. It is the second most commonly reported bacterial STI in the United States, with more than 700,000 new cases estimated each year. Despite being curable with the right antibiotics, gonorrhea remains a major public health concern — largely because it so often causes no symptoms at all, especially in women, allowing it to spread silently and cause serious long-term damage before it is ever detected.

The good news: gonorrhea is curable. A single injection of ceftriaxone at a clinic or doctor's office clears the infection in most people. The concerning news: the bacteria that cause gonorrhea have developed resistance to virtually every class of antibiotic ever used against them — penicillin, tetracycline, fluoroquinolones — and are now showing early signs of resistance to the cephalosporin antibiotics that are our last reliable option. The World Health Organization has designated N. gonorrhoeae as a priority pathogen requiring urgent new treatment development.

If you have been told you have gonorrhea, the most important things to know are: get treated right away, make sure your partner(s) also get treated, and get retested a few weeks later to confirm the infection is gone. Untreated gonorrhea can cause permanent reproductive damage, increase your risk of HIV, and spread to others who may never know they have it.

Back to Table of Contents

Epidemiology

Gonorrhea is a global problem. The World Health Organization estimated 82 million new cases worldwide in 2020 alone. In the United States, the CDC reported 677,769 gonorrhea cases in 2020 — a number that has risen substantially over the past decade after hitting a historic low around 2009.

Who is most affected:

• Young adults ages 15–24 account for roughly 45% of all reported cases. This is partly behavioral (more sexual partners, less consistent condom use) and partly because young people may be less likely to seek regular STI screening.
• Men who have sex with men (MSM) carry a disproportionate share of the burden. Pharyngeal (throat) and rectal gonorrhea are particularly common in this group, and both are often asymptomatic — which means they frequently go undetected and untreated.
• Racial and ethnic disparities are pronounced and reflect broader inequities in access to healthcare, screening, and treatment rather than any biological difference. Black Americans are diagnosed at rates roughly 8 times higher than white Americans, according to CDC surveillance data.
• Rising antibiotic resistance is the most alarming epidemiological trend. The proportion of N. gonorrhoeae isolates with reduced susceptibility to azithromycin — until recently a backbone of combination therapy — has risen sharply, prompting the CDC to revise its treatment guidelines in 2020 to remove azithromycin from standard regimens entirely.

Many cases go unreported or undiagnosed, so actual infection numbers are substantially higher than official figures. Most women with gonorrhea have no symptoms, meaning they may not seek testing until complications arise.

Back to Table of Contents

Pathophysiology

Neisseria gonorrhoeae is a gram-negative diplococcus — meaning it appears as pairs of kidney-shaped bacteria that stain pink (not purple) with the Gram stain technique. It is a remarkably sophisticated pathogen that has evolved multiple strategies for infecting humans and evading our immune defenses.

How it infects cells: The bacteria use hair-like projections called pili to attach to the non-ciliated columnar epithelial cells that line the urethra, cervix, rectum, throat, and eyes. Once attached, the bacteria are taken up into the cells and survive inside them — which is why gonorrhea is harder to clear than a simple surface infection. Outer membrane proteins called Opa proteins help the bacteria home in on specific tissues (tissue tropism) and also help them evade recognition by the immune system.

How it causes symptoms: The bacteria's outer surface contains a molecule called lipooligosaccharide (LOS), which functions as an endotoxin — it triggers a powerful inflammatory response. This inflammation is responsible for the painful urethral discharge, redness, and swelling seen in symptomatic cases. In women, this inflammation can ascend through the reproductive tract to cause pelvic inflammatory disease.

How it evades your immune system: N. gonorrhoeae is an expert at dodging the body's defenses. Its outer surface proteins change constantly (antigenic variation), making it difficult for the immune system to build lasting immunity — which is why people can be reinfected repeatedly. Porin proteins in its outer membrane help it resist complement-mediated killing (a key immune weapon against bacteria in the bloodstream). This explains why disseminated infection can occur in some people whose complement system is compromised.

Antibiotic resistance mechanisms are described in detail in the Antimicrobial Resistance section, but the key mechanisms include efflux pumps (which actively pump antibiotics out of the bacterial cell), altered penicillin-binding proteins (which prevent beta-lactam antibiotics from working), and beta-lactamase enzymes (which chemically destroy penicillin-type antibiotics).

Back to Table of Contents

Sites of Infection and Clinical Presentation

Gonorrhea can infect several different parts of the body, and the symptoms — or lack of symptoms — vary significantly depending on where the infection takes hold.

Urethral infection (most common in men)

In men, gonorrhea most often infects the urethra (the tube that carries urine out of the body). Symptoms typically appear 1–14 days after exposure and include:

• Painful or burning urination (dysuria)
• A discharge from the penis that is yellow, white, or greenish (mucopurulent or purulent)
• Sometimes: redness or swelling at the tip of the penis

However, up to 10–15% of men with urethral gonorrhea have no symptoms at all.

Cervical infection (most common in women)

In women, the cervix (the lower part of the uterus) is the most common infection site. This is where gonorrhea's silent nature is most dangerous: 50–70% of women with cervical gonorrhea have no symptoms whatsoever. When symptoms do occur, they may include:

• Increased or unusual vaginal discharge
• Painful urination
• Bleeding between periods
• Pain during sexual intercourse

Because symptoms are so often absent, many women are not diagnosed until a complication such as pelvic inflammatory disease develops — or until a sexual partner tests positive and prompts their own testing.

Rectal infection

Rectal gonorrhea can affect anyone who has receptive anal sex. It is often completely asymptomatic. When symptoms do occur, they include:

• Rectal pain or discomfort
• Discharge from the rectum
• Tenesmus (a persistent feeling of needing to have a bowel movement)
• Bleeding

Pharyngeal infection (throat)

Gonorrhea of the throat is acquired through oral sex. It is almost always asymptomatic — most people have no idea they have it. Occasionally, a mild sore throat may develop. Pharyngeal gonorrhea is an important reservoir because it is frequently missed, and the throat environment may actually encourage the development of antibiotic resistance through contact with other oral bacteria that carry resistance genes.

Conjunctival infection (eyes)

Gonococcal eye infection (gonococcal ophthalmia) can occur in two settings:

• Newborns (ophthalmia neonatorum): A baby can acquire gonorrhea from an infected mother during passage through the birth canal. This causes a severe, purulent (pus-producing) conjunctivitis that, if untreated, can lead to corneal damage and blindness. This is why newborns routinely receive erythromycin eye drops (or povidone-iodine in some countries) immediately after birth.
• Adults: Usually acquired by touching the eye with a hand contaminated with genital secretions. Causes a severe, rapidly progressing purulent conjunctivitis requiring urgent treatment.

Disseminated Gonococcal Infection (DGI)

In 1–3% of untreated cases, N. gonorrhoeae enters the bloodstream and spreads to other parts of the body — a condition called disseminated gonococcal infection (DGI). This is more common in women (possibly because cervical infections often go untreated longer). DGI most commonly presents as the arthritis-dermatitis syndrome, which includes:

• Tenosynovitis: Painful inflammation of the tendons and their sheaths, especially in the hands, wrists, ankles, and feet
• Migratory polyarthralgia: Joint pain that moves from joint to joint
• Dermatitis: A characteristic skin rash of small pustular or petechial (tiny red pinpoint) spots, often on the palms, soles, and extremities

Less commonly, DGI can progress to frank septic arthritis (bacteria in a single large joint, usually the knee or wrist), and rarely to gonococcal endocarditis (infection of the heart valves) or meningitis — both life-threatening emergencies requiring hospitalization and IV antibiotics.

Back to Table of Contents

Complications

The long-term consequences of untreated or inadequately treated gonorrhea can be severe. Most complications result from the bacteria spreading from the original infection site to other parts of the reproductive system.

Pelvic Inflammatory Disease (PID)

PID is the most important complication of gonorrhea in women. It occurs when gonorrhea (sometimes combined with chlamydia or other bacteria) ascends from the cervix into the uterus, fallopian tubes, and ovaries. Consequences include:

• Tubal factor infertility: Scarring of the fallopian tubes from repeated or severe PID can permanently block the tubes, making it impossible for an egg to travel to the uterus. Even a single episode of PID increases a woman's risk of infertility. After three or more episodes, roughly 40–50% of affected women experience infertility.
• Ectopic pregnancy: Tubal scarring also dramatically increases the risk of an ectopic (tubal) pregnancy — a potentially life-threatening emergency in which a fertilized egg implants in the fallopian tube rather than the uterus.
• Chronic pelvic pain: PID-related scarring and adhesions can cause persistent pelvic pain that lasts for years.
• Tubo-ovarian abscess: A severe form of PID in which a pocket of pus forms in or around the ovary, often requiring hospitalization and sometimes surgery.

Fitz-Hugh-Curtis Syndrome

In some women with PID, the infection spreads to the surface of the liver (perihepatitis), causing inflammation of the liver capsule. This produces right upper abdominal pain that can mimic gallbladder disease or appendicitis. Named after the physicians who first described it in the 1930s.

Epididymo-orchitis in men

If gonorrhea ascends from the urethra in men, it can infect the epididymis (the coiled tube where sperm mature behind each testicle), causing pain, swelling, and tenderness. Rarely, if both testicles are affected and treatment is delayed, this can lead to infertility in men as well.

Increased HIV susceptibility

Gonorrhea — like other STIs that cause inflammation and disruption of the genital mucosa — significantly increases the risk of HIV transmission in both directions. Inflammation recruits immune cells (the very cells HIV targets) to the genital area, and mucosal disruption creates easier entry points for the virus. Treating gonorrhea is therefore also an important HIV prevention strategy.

Back to Table of Contents

Diagnosis

Getting the right test matters. Gonorrhea diagnosis has evolved significantly in recent years, and the type of test recommended depends on where you are being tested and what body sites may be infected.

NAAT (Nucleic Acid Amplification Test) — the gold standard

NAAT is the most sensitive and specific test available for gonorrhea. It detects the DNA of N. gonorrhoeae directly, which means it can find the infection even when bacterial numbers are low. NAAT can be performed on:

• Urine (preferred for testing men — a first-catch urine sample works well)
• Vaginal swab (self-collected swabs are acceptable and have excellent sensitivity — you do not need a pelvic exam for this test)
• Cervical swab (collected during a pelvic exam)
• Rectal swab (important for people who have receptive anal sex)
• Pharyngeal (throat) swab (important for people who perform oral sex)

NAAT cannot tell you whether the gonorrhea strain you are infected with is resistant to antibiotics — it only detects presence or absence of the bacteria.

Culture — still important for resistance testing

Bacterial culture (growing the bacteria in a lab) is less sensitive than NAAT for routine diagnosis, but it remains essential for antibiotic susceptibility testing. If you do not respond to treatment as expected, a culture helps identify which antibiotics the strain is resistant to. Clinicians should request gonorrhea culture in any case of suspected treatment failure or when treating patients in outbreak settings. Culture requires a swab of the infected site and must be transported and processed quickly.

Gram stain

In men with symptomatic urethral discharge, a Gram stain of the discharge — looking for the characteristic gram-negative diplococci inside white blood cells — has about 95% sensitivity. It gives a fast, same-visit answer in symptomatic men. However, Gram stain is not reliable in women (sensitivity only 50–60% for cervical specimens) and should not be used to rule out gonorrhea in women or in asymptomatic individuals of any gender.

Point-of-care tests

Rapid point-of-care NAAT tests are now emerging that can give results in under an hour without needing to send samples to an outside lab. These are particularly valuable in resource-limited settings and for immediate treatment decisions. Availability is still limited but expanding.

Who should be tested?

The CDC recommends annual gonorrhea screening for:

• All sexually active women under age 25
• Older women with risk factors (new or multiple partners, inconsistent condom use)
• MSM at every clinical encounter for HIV care, and at least every 3–6 months for those with multiple partners
• Anyone who reports symptoms consistent with gonorrhea
• Sexual partners of someone diagnosed with gonorrhea
• Pregnant women (screen at first prenatal visit; rescreen in third trimester if at risk)

Back to Table of Contents

Treatment

The good news about gonorrhea is that it remains curable. The treatment approach has changed in recent years, however — it is important to follow current guidelines, not older information from the internet or previous prescriptions.

Current CDC recommendation (updated 2020)

For uncomplicated gonorrhea (urogenital, rectal, or pharyngeal) in adults and adolescents:

• Ceftriaxone 500 mg given as a single intramuscular (IM) injection
• If the patient weighs 150 kg (330 lbs) or more: ceftriaxone 1 gram IM single dose

That's it — one shot, one visit, gone (pending a test of cure). This is a significant simplification from older dual-therapy regimens.

The azithromycin change — important

Prior to 2020, CDC guidelines recommended combining ceftriaxone with azithromycin (an antibiotic taken by mouth). This dual-therapy approach is no longer recommended. The change was driven by a dramatic rise in resistance to azithromycin among gonorrhea strains — adding it to treatment provides little benefit and accelerates the development of macrolide class resistance. If a provider offers you "the old two-pill treatment," it is worth asking whether they are aware of the 2020 guideline update.

If ceftriaxone is unavailable

In rare situations where ceftriaxone cannot be obtained:

• Gentamicin 240 mg IM single dose plus azithromycin 2 g orally single dose (this combination is used only when ceftriaxone is truly unavailable)

Treatment for specific situations

• Chlamydia co-infection: If chlamydia has not been excluded by NAAT, add doxycycline 100 mg twice daily for 7 days to cover chlamydia as well.
• Pelvic Inflammatory Disease (PID): Ceftriaxone 500 mg IM single dose, plus doxycycline 100 mg twice daily for 14 days, plus metronidazole 500 mg twice daily for 14 days (metronidazole covers anaerobic bacteria involved in PID). Severe or hospitalized PID uses IV antibiotics.
• Disseminated Gonococcal Infection (DGI): Ceftriaxone 1 gram IV or IM every 24 hours until symptoms improve substantially (usually 24–48 hours), then step down to an oral agent to complete 7 days of total treatment. Gonococcal endocarditis or meningitis requires 4 weeks or 2 weeks of IV treatment respectively.
• Pregnancy: Ceftriaxone 500 mg IM single dose is safe in pregnancy. Doxycycline is contraindicated in pregnancy; azithromycin 1 g orally (single dose) is used to cover chlamydia if needed.
• Neonatal gonococcal ophthalmia: Ceftriaxone 25–50 mg/kg IV or IM (maximum 250 mg) single dose.

Partner treatment

Treatment is not complete without treating your recent sexual partners. Partners from the past 60 days (or the most recent partner if the last sexual contact was more than 60 days ago) should be tested and treated. Expedited partner therapy (EPT) — where you bring home or receive a prescription for your partner without them seeing a provider — is legal in most US states and endorsed by the CDC when it is not possible to get a partner to a clinic quickly.

Test of cure

The CDC recommends a test of cure (retesting to confirm the infection has cleared) 1–2 weeks after treatment, particularly for pharyngeal gonorrhea (which is harder to cure) and in any case where antibiotic resistance is a concern. A routine follow-up NAAT 3 months after treatment is also recommended to detect reinfection, which is very common.

Back to Table of Contents

Antimicrobial Resistance

Neisseria gonorrhoeae has a remarkable and troubling history of developing resistance to every antibiotic class used against it. Understanding this history helps explain why today's treatment guidelines are what they are — and why ongoing surveillance and research are so critical.

The historical progression of resistance

• 1940s–1970s: Penicillin era. Penicillin was the first effective gonorrhea treatment and worked beautifully for decades. By the late 1970s, penicillinase-producing strains (PPNG) — bacteria that make an enzyme that destroys penicillin — had spread globally. Penicillin was retired from gonorrhea treatment.
• 1970s–1980s: Tetracycline. Tetracycline resistance followed a similar pattern and became widespread, driven by both chromosomal mutations and a plasmid carrying a high-level resistance gene. Tetracyclines were phased out for gonorrhea.
• 1980s–2007: Fluoroquinolones (ciprofloxacin). Fluoroquinolones were once a convenient single-dose oral option. Resistance emerged rapidly — particularly in Asia, then in California among MSM — and by 2007, the CDC recommended stopping fluoroquinolone use for gonorrhea entirely in the US.
• 2007–present: Cephalosporins. Ceftriaxone (injectable) and cefixime (oral) became the last reliable treatment options. Cefixime resistance has already emerged and spread, which is why the oral cephalosporin has been dropped from guidelines. Ceftriaxone resistance remains rare but has been documented — including treatment failures in several countries. This is the scenario that public health officials fear most.
• 2015–present: Azithromycin. Once used as part of combination therapy, macrolide resistance has risen sharply. The CDC removed azithromycin from standard gonorrhea regimens in 2020 in response.

Resistance mechanisms

Gonorrhea uses multiple, layered mechanisms to resist antibiotics:

• Efflux pumps (MtrCDE system): A molecular pump in the bacterial cell membrane that actively expels a wide range of antibiotics — including macrolides, beta-lactams, and tetracyclines — before they can reach their targets inside the cell.
• Altered penicillin-binding proteins (PBP2): Mutations in the gene encoding PBP2 (the target of cephalosporins and penicillins) reduce the affinity of these antibiotics for their target, so higher concentrations are needed to kill the bacteria — concentrations that may not be achievable in tissues.
• Beta-lactamase (TEM-1 type): An enzyme encoded on a mobile plasmid (a small piece of DNA that can transfer between bacteria) that chemically hydrolyzes and inactivates penicillin-class antibiotics.
• Mosaic penA alleles: Recombinant hybrid genes — parts of which have been acquired from naturally occurring oral Neisseria species — that dramatically reduce cephalosporin susceptibility. These are the most worrying resistance mutations from a treatment perspective.

Surveillance

The CDC's Gonococcal Isolate Surveillance Project (GISP) and the WHO's Global Gonococcal Antimicrobial Surveillance Programme (GASP) continuously monitor resistance patterns by culturing and testing gonorrhea isolates from clinics around the world. This surveillance is how treatment guidelines are updated — and it is the early warning system for detecting new resistance threats before they become untreatable.

Back to Table of Contents

Prevention

There is currently no vaccine for gonorrhea, which makes behavioral and screening strategies the primary prevention tools available.

Condoms

Consistent and correct condom use substantially reduces — though does not eliminate — the risk of gonorrhea transmission. Studies suggest condoms reduce gonorrhea transmission by approximately 85% when used consistently. They work by preventing direct contact between mucous membranes and infected secretions. Key points:

• Condoms protect against urethral and cervical gonorrhea effectively
• They provide less protection for pharyngeal gonorrhea (because the throat may be exposed during oral sex before or after condom use)
• Dental dams can reduce risk during oral-vaginal or oral-anal contact

Partner notification

When you are diagnosed with gonorrhea, notifying recent partners is essential — both to protect their health and to prevent reinfection. Expedited partner therapy (EPT), where partners receive treatment without an in-person clinic visit, has been shown to reduce reinfection rates and is endorsed by the CDC for gonorrhea. Many health departments can assist with anonymous partner notification if you are uncomfortable contacting partners directly.

Regular STI screening

Because gonorrhea so often causes no symptoms, regular testing is the primary way to catch infections early — before complications develop and before unknowing transmission to others. Regular screening is recommended for:

• All sexually active women under age 25 — at least annually
• MSM with multiple or anonymous partners — every 3–6 months, including rectal and pharyngeal sites, not just urine
• People with HIV — at every clinical care visit
• Anyone starting a new sexual relationship (consider testing both partners before stopping condoms)

Vaccine development

A gonorrhea vaccine does not yet exist, but this is an active area of research. Interestingly, observational studies have found that people who received the meningococcal B (MenB) vaccine (licensed to prevent a related Neisseria species) appear to have reduced rates of gonorrhea — suggesting some cross-reactive immunity. This finding has energized vaccine research and clinical trials are underway to determine whether MenB vaccines can be adapted or whether a dedicated gonorrhea vaccine is feasible.

Back to Table of Contents

Research Advances

The growing threat of antibiotic-resistant gonorrhea has driven significant investment in new treatment and prevention strategies.

Whole-genome sequencing for resistance surveillance

Traditional culture-based resistance testing takes days and only catches a limited number of resistance markers. Whole-genome sequencing (WGS) of gonorrhea isolates can rapidly identify all known resistance mutations, track the spread of resistant strains geographically, and detect emerging resistance patterns before they become clinical problems. Public health labs in several countries now use WGS routinely for gonorrhea surveillance.

Zoliflodacin — a new class of antibiotic

Zoliflodacin is an oral antibiotic from a new class (spiropyrimidinetrione) that works by a completely different mechanism from any existing gonorrhea treatment — it targets a bacterial enzyme called topoisomerase II. Because it uses a new target, it is active against strains resistant to all existing antibiotic classes. Phase 3 clinical trials have shown zoliflodacin to be as effective as ceftriaxone for uncomplicated gonorrhea, and it has the major advantage of being an oral pill rather than an injection. Regulatory approval is expected in the near term.

Gepotidacin

Gepotidacin is another new antibiotic (triazaacenaphthylene class) with a novel bacterial target (topoisomerase IV). Like zoliflodacin, it is oral and active against multidrug-resistant gonorrhea. Phase 3 trials have shown promising efficacy, particularly for urogenital gonorrhea. Gepotidacin adds a second potential oral option that could help preserve ceftriaxone effectiveness by giving clinicians alternatives.

Gonorrhea vaccine research

Following the serendipitous observation that MenB vaccine recipients had lower gonorrhea rates, researchers are now working to understand which specific antigens (surface proteins) might confer cross-protection against N. gonorrhoeae and whether these can be incorporated into a dedicated gonorrhea vaccine. The outer membrane vesicle (OMV) component of some MenB vaccines appears to be the key protective element. Clinical trials of MenB vaccination specifically for gonorrhea prevention are in progress.

Point-of-care resistance testing

Molecular tests that can detect specific resistance genes in a clinic visit — without waiting for culture results — are being developed and validated. These would allow providers to choose the right antibiotic immediately rather than prescribing empirically and potentially using an ineffective drug.

Back to Table of Contents

Key Research Papers

1. Workowski KA et al. — CDC Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. — PMID: 34292926
2. Workowski KA, Bolan GA — Sexually Transmitted Diseases Treatment Guidelines, 2015. CDC/MMWR. — PMID: 25621840
3. Unemo M et al. — Gonorrhea (Nature Reviews Disease Primers, 2019). — PMID: 30485276
4. Patton ME et al. — Primary and secondary syphilis — United States, 2005–2013. MMWR. — PMID: 22461882
5. PubMed: gonorrhea ceftriaxone resistance WHO
6. PubMed: gonorrhea NAAT diagnosis sensitivity specificity
7. PubMed: disseminated gonococcal infection arthritis dermatitis syndrome
8. PubMed: gonorrhea pelvic inflammatory disease infertility tubal factor
9. PubMed: Neisseria gonorrhoeae efflux pump MtrCDE antibiotic resistance
10. PubMed: zoliflodacin gonorrhea phase 3 clinical trial
11. PubMed: meningococcal B vaccine gonorrhea protection cross-reactive
12. PubMed: gonorrhea azithromycin resistance CDC 2020 guidelines update

Back to Table of Contents

PubMed Research Papers

1. PubMed: gonorrhea treatment ceftriaxone single dose
2. PubMed: Neisseria gonorrhoeae antibiotic resistance mechanisms
3. PubMed: gonorrhea epidemiology United States CDC surveillance
4. PubMed: gonorrhea asymptomatic women cervical infection
5. PubMed: gonorrhea pharyngeal rectal MSM screening
6. PubMed: gonococcal ophthalmia neonatorum prevention newborn
7. PubMed: gonorrhea expedited partner therapy reinfection prevention
8. PubMed: gonorrhea HIV susceptibility risk interaction
9. PubMed: gonorrhea whole genome sequencing surveillance resistance
10. PubMed: gepotidacin gonorrhea clinical trial topoisomerase
11. PubMed: gonorrhea condom efficacy prevention transmission
12. PubMed: Fitz-Hugh-Curtis syndrome perihepatitis gonorrhea chlamydia

Back to Table of Contents

Connections

• Chlamydia
• Syphilis
• HPV
• HIV / AIDS
• Herpes Simplex
• Infertility
• Infectious Disease
• All Conditions
• Lab Tests

Back to Table of Contents

Featured Videos